The effect of Bushen Culuan Decoction on anovulatory infertile women among 6 different diseases: a study protocol for a randomized, double-blinded, positively controlled, adaptive multicenter clinical trial

Kun Ma, Yun Shi, Junqin He, Xiuxiang Teng, Rongyu Wang, Guohua Wang, Yanan Yu, Yanxia Chen, Linjuan Gong, Yuan Yuan, Huixian Zhang, Bochao Yuan, Chenhui Zhang, Kun Ma, Yun Shi, Junqin He, Xiuxiang Teng, Rongyu Wang, Guohua Wang, Yanan Yu, Yanxia Chen, Linjuan Gong, Yuan Yuan, Huixian Zhang, Bochao Yuan, Chenhui Zhang

Abstract

Background: Anovulation is one of the main causes of female infertility. This study will evaluate the effectiveness and safety of Bushen Culuan Decoction for anovulatory infertility caused by six diseases, including anovulatory abnormal uterine bleeding, polycystic ovarian syndrome, hyperprolactinemia, luteinized unruptured follicle syndrome, corpus luteum insufficiency, and premature ovarian insufficiency.

Methods: This is a randomized, double-blinded, double-dummy, parallel, positively controlled, adaptive, multicenter clinical trial. All participants will be randomly allocated by a central randomization system to the treatment group or the control group in a 1:1 ratio. The treatment group will undergo a 14-day treatment with Bushen Culuan Decoction 13 g three times a day and a 5-day treatment with clomiphene citrate placebo tablets 50 mg once a day starting on day 5 of every menstrual period. The control group will undergo a 14-day treatment with Bushen Culuan Decoction placebo 13 g three times a day and a 5-day treatment with clomiphene citrate tablets 50 mg once a day from day 5 in every menstrual period. The whole treatment will last through 3 menstrual periods or 6 menstrual periods, depending on whether ovulation is regained in the first 3 menstrual periods. All statistical analyses will be performed in SPSS 21.0 (SPSS, Chicago, Illinois, USA), and a p value < 0.05 will be considered statistically significant.

Discussion: The objective of this RCT is to evaluate whether Bushen Culuan Decoction enables a higher pregnancy rate than clomiphene citrate in women with anovulatory infertility and to identify the anovulatory diseases for which Bushen Culuan Decoction has higher effectiveness .This study has been approved by the Medical Ethics Committee of Xiyuan Hospital China Academy of Chinese Medical Sciences (No. 2017XLA037-2). The results of this study will be offered for publication in peer-reviewed journals.

Trial registration: ClinicalTrials.gov NCT03709849 . Registered on 19 November 2018.

Keywords: Anovulatory infertility; Basket design; Randomized controlled trial.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study flow chart. AMH: anti-Mullerian hormone; INHB: inhibin B; PI: pulsatility index
Fig. 2
Fig. 2
Traditional Chinese Medicine symptom score

References

    1. Serour GI, Aboulghar M, Al Bahar A, et al. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction. Reprod Biol Endocrinol. 2014;12(1):52–61. doi: 10.1186/1477-7827-12-52.
    1. Yuan YE, Sheng DQ. New theory and technology of obstetrics and gynecology [M], vol. 155. Shanghai: Shanghai Scientific and Technological Education Publishing House; 1998.
    1. Li R, Qiao J. Reproductive endocrine disease: diagnosis and management, vol. 361. Beijing: Peking University Medical Press; 2012. p. 437–48.
    1. Ren Y, Li R, Fan YH, et al. High risk factors of severe ovarian hyperstimulation syndrome. Reprod Contraception. 2016;36:719–25,744.
    1. Lv YL, Wan YL, Peng XL, et al. Causes of bleeding after transvaginal ultrasonography-guided oocyte retrieval for IVF-ET and nursing care. J Nurs Sci. 2014;29:37–38.
    1. Santos MA, Kuijk EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction. 2010;139(1):23–34. doi: 10.1530/REP-09-0187.
    1. Huang HF, Luo Q, Zhu YM. Progress of reproductive security. J Int Reprod Health Family Plan. 2012;31:334–340.
    1. Rimm AA, Katayama AC. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012;366(19):1803–1813. doi: 10.1056/NEJMoa1008095.
    1. Zhou D, Tang XR, Lin HY, et al. Meta analysis of traditional Chinese medicine in treatment of infertility caused by kidney deficiency. J Hunan Univ Chin Med. 2017;37:961–965.
    1. Luo L, Chen SQ. Meta-analysis of method of reinforcing kidney and activating blood circulation for ovulation failure infertility. World J Integr Trad Western Med. 2015;10:300–302.
    1. Fan XD, Ma K, Shan J, Jin XT. Systematic evaluation of kidney-tonifying and blood-activating traditional Chinese medicines in treatment of ovulatory disorder infertility. China J Chinese Materia Medica. 2013;38(19):3382–3387.
    1. Ma K, Li M. Study on the mechanism of Bushen Culuan Chongji treating “kidney deficiency and blood stasis” in ovulatory dysfunctional infertility. China J Chinese Materia Medica. 2017;42(23):4445–4450. doi: 10.19540/j.cnki.cjcmm.20171012.004.
    1. Ma K. The influence of Bushen Culuan Decoction in affecting ovulation and luteal function in experimental rat. Fujian J TCM. 1997;28:3–4.
    1. Ma K, Liu YF, He JQ, Li M, Shan J. A multi-center, randomized, double-blinded clinical study on Bushen Huoxue in treatment of ovulatory dysfunction caused infertility. China J Chinese Materia Medica. 2015;40(20):3911–3915.
    1. Zegers-Hochschild F, Adamson GD, de Mouzon J, on behalf of ICMART and WHO et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Hum Reprod. 2009;24(11):2683–2687. doi: 10.1093/humrep/dep343.
    1. Gynecologic endocrinology group, Obstetrics and Gynecology branch of Chinese Medical Association Diagnosis and treatment guideline of abnormal uterine bleeding. Chin J Obstetr Gynecol. 2014;49:801–806.
    1. Cui LL, Chen JZ. Diagnosis criteria and guideline for the diagnosis and treatment of PCOS. J Int Reprod Health Family Planning. 2011;30:405–408.
    1. Gynecologic endocrinology group, Obstetrics and Gynecology branch of Chinese Medical Association Diagnosis and treatment consensus of female hyperprolactinemia. Chin J Obstetr Gynecol. 2016;51:161–168.
    1. Cheng J. Practical integrated Chinese and Western medicine diagnosis and treatment for infertility. 1. Beijing: China Press of Traditional Chinese Medicine; 1999. pp. 358–363.
    1. Sun B, Liu P, Ye H, et al. Luteal phase support with progesterone supplementation consensus. Reprod Contraception. 2015;35:1–8.
    1. The ESHRE Guideline Group on POI. Webber L, Davies M, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi: 10.1093/humrep/dew027.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する